Drug intelligence / Profile preview

fH1 + DSP-0546LP

Development stage
Unknown
Lead developer
Sumitomo Pharma
Modality
Small Molecules, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**fH1 + DSP-0546LP** is a combination investigational universal influenza vaccine candidate composed of two components: - **fH1**: a post-fusion hemagglutinin antigen engineered to expose highly conserved regions of influenza hemagglutinin, aiming for broad immunogenicity across influenza virus strains. - **DSP-0546LP**: a proprietary lipid-formulated small molecule agonist of Toll-like receptor 7 (TLR7), acting as a vaccine adjuvant to enhance the quantity, quality, and durability of the immune response, with strong Th1 polarization and increased antibody-dependent cellular cytotoxicity (ADCC) against diverse influenza strains. Developed to provide broader and more durable protection compared to conventional seasonal influenza vaccines, fH1 + DSP-0546LP is undergoing phase 1 clinical trials in healthy adults for both safety and immunogenicity.

Other names
fH1/DSP-0546LP
02

Targets

TLR7 (Toll-like receptor 7)HA-LAH (Influenza hemagglutinin long alpha helix)

Beyond the preview

Go deeper on fH1 + DSP-0546LP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fH1 + DSP-0546LP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call